Status:
TERMINATED
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus
Lead Sponsor:
ViaCyte
Collaborating Sponsors:
California Institute for Regenerative Medicine (CIRM)
Conditions:
Type 1 Diabetes Mellitus
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years. It will also test if VC-01 is a...
Eligibility Criteria
Inclusion
- Men and women (non-pregnant and non-childbearing potential)
- Diagnosis of type 1 diabetes mellitus for at least 3 years
- Stable diabetic treatment
- Willingness to use a continuous glucose meter
- Acceptable candidate for implantation
Exclusion
- Advanced complications associated with diabetes
- Immunosuppressive therapy
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT02239354
Start Date
September 1 2014
End Date
December 1 2017
Last Update
March 24 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at San Diego
San Diego, California, United States
2
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7